PEMETREXED DISODIUM

Peak

pemetrexed disodium

NDAINTRAVENOUSSOLUTION
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
15

Mechanism of Action

folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis…

Clinical Trials (5)

NCT01784640Phase 1Completed

Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer

Started Jan 2014
13 enrolled
Recurrent Non-small Cell Lung CancerSquamous Cell Lung CancerStage IV Non-small Cell Lung Cancer
NCT01085630Phase 2Completed

Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy

Started Apr 2010
72 enrolled
Malignant Mesothelioma
NCT01041781Phase 3Terminated

Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Started Feb 2010
313 enrolled
Lung Cancer
NCT00454194Phase 2Completed

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Started Sep 2007
110 enrolled
Lung Cancer
NCT00369629Phase 1Terminated

Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome

Started Aug 2006
14 enrolled
Lymphoma